Chromocell Therapeutics Co. (NYSE:CHRO – Get Free Report)’s stock price traded down 4.7% during mid-day trading on Thursday . The stock traded as low as $1.60 and last traded at $1.63. 8,474 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 1,564,620 shares. The stock had previously closed at $1.71.
Chromocell Therapeutics Price Performance
The company has a 50-day moving average price of $1.37 and a 200-day moving average price of $0.96.
Chromocell Therapeutics Company Profile
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.
Featured Stories
- Five stocks we like better than Chromocell Therapeutics
- 3 Fintech Stocks With Good 2021 Prospects
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Chromocell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromocell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
